Why Early QC Planning Matters in Cell and Gene Therapy - Poll - MDSpire

Why Early QC Planning Matters in Cell and Gene Therapy

Late-stage CMC setbacks often begin with early QC decisions that shape cell and gene therapy timelines, costs, and regulatory outcomes

  • By

  • Laurent Claisse

  • June 30, 2026

  • 9 min

Share

Original Source(s)

Why Early QC Planning Matters in Cell and Gene Therapy

  • by Laurent Claisse

  • June 30, 2026

Related Content

Cutaneous laser treatment of port-wine stains and its impact on ocular manifestations in Sturge–Weber syndrome

Iron overload disrupts bone homeostasis via TfR1-dependent ferroptosis and cGAS/STING-driven pyroptosis in pyogenic spondylitis

Clinicopathological and molecular characteristics of primary pulmonary choriocarcinoma: a case report and systematic review